Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.91 |
| ▸ | NR1H2 | P55055 | 19/20 | 0.91 |
| ▸ | NR1H3 | Q13133 | 19/20 | 0.91 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.91 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197815 | 0.95 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL779338 | 0.95 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL16407945 | 0.92 | RXRA (0.89) | RXRANR1H2NR1H3NR1I2PTGS2 | |
| SCHEMBL16407950 | 0.89 | RXRA (0.89) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL781718 | 0.86 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL15783180 | 0.83 | RXRA (0.87) | RXRANR1H2NR1H3NR1I2PTGS2 | |
| SCHEMBL779391 | 0.83 | RXRA (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL16407940 | 0.83 | NR1H2 (0.77) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL16407947 | 0.83 | NR1H2 (0.89) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL16407956 | 0.81 | RXRA (0.89) | RXRANR1H2NR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20180153833-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2018-06-07 | — | — | US | disclosed |
| US-9962348-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170319525-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-09 | — | — | US | disclosed |
| US-9707195-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9526710-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160331726-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2016-11-17 | — | — | US | disclosed |
| US-9399028-B2 | Treatment of drug resistant cancer | THE ROCKEFELLER UNIVERSITY (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150073053-A1 | TREATMENT OF DRUG RESISTANT CANCER | ROCKEFELLER UNIVERSITY (THE) (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150023955-A1 | Treatment and Diagnosis of Melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319525-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | RXRA 20/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | RXRA 20/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20150073053-A1 | TREATMENT OF DRUG RESISTANT CANCER | ABCC1, TSG101, NTPCR | RXRA 2119/4885NR1H2 3830/4885NR1H3 3331/4885 |
| US-20160331726-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
| US-20180153833-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
| US-20150023955-A1 | Treatment and Diagnosis of Melanoma | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.